US Stock Movement: Xeris Biopharma surged on October 5th due to acquisition interest, Phase III results for XP-8121, and revenue growth
Bitget异动解读2026/10/05 16:30Xeris Biopharma's Significant Surge on October 5 Explained
Keywords: acquisition interest, XP-8121 Phase III, revenue growth
1. On September 29, it was reported that H Lundbeck had been working with advisors to evaluate the possibility of acquiring Xeris. The discussions remain in the preliminary stages; Xeris stated that the company is "not for sale" and will continue to develop and commercialize its therapeutic product portfolio.
2. On September 9, the company stated that the registrational Phase III study plan for XP-8121 is scheduled to commence on time at the end of 2026, with primary results expected to be announced in the second half of 2028. FDA approval and commercialization in the United States is anticipated for 2030, with peak net revenue potential estimated between $1 billion and $3 billion.
3. On August 6, the company announced total revenue of $92.1 million for the second quarter, a 29% year-on-year increase; net product revenue reached $91 million, a 34% year-on-year increase. Among these, Recorlev’s net revenue was $56.8 million, up 81% year-on-year, and full-year total revenue guidance for 2026 was adjusted to $385 million to $390 million.
(Disclaimer: This content is generated by AI technology based on the summary of publicly available information, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street banks launch $60 billion chip deal for Broadcom and Anthropic
According to the Financial Times, Wall Street banks have launched a record-breaking $60 billion chip deal involving Broadcom and Anthropic.
Nasdaq rises 1.05%, Nvidia surges 2.12% leading active stocks
The Dow Jones closed up 0.18%, the Nasdaq rose 1.05%, and the S&P 500 gained 0.66%. Among the stocks with the highest trading volumes, Nvidia rose 2.12%, SpaceX surged 7.63%, Micron Technology fell 1.02%, and Tesla increased 2.2%.
Fitch says North American oil hedging currently faces book losses, natural gas traders lock in prices for 2028
Fitch Ratings has published a related assessment showing that oil hedging operations in North America have currently resulted in paper losses, while natural gas producers are moving to lock in favorable prices for 2028. It is understood that hedging activities by energy companies are primarily intended to counter commodity price fluctuations and stabilize operating cash flows. The recent paper losses in oil hedging are directly linked to the volatility in international oil prices. Meanwhile, natural gas producers' decisions to secure advantageous prices years in advance reflect the industry’s clear expectations regarding future supply and demand dynamics and price trends for natural gas. This early positioning aims to safeguard future profit margins and mitigate the operational uncertainties that potential market price fluctuations may bring.
Meta and Microsoft strive to reduce employees’ reliance on Claude: Meta’s internal usage has halved, and Microsoft has cut its budget by one-third.
Microsoft's internal Claude budget has been reduced by more than one-third from its peak, and the number of internal Claude Code users at Meta has dropped from around 60,000 to 30,000. Both companies emphasize that external customer demand is still growing, but the decline in internal usage puts pressure on Anthropic. According to Anthropic's IPO prospectus, two major clients together contributed about 25% of its revenue. Although the prospectus does not name specific clients, it is highly likely that Meta and Microsoft are these two clients or among them.
Crypto prices
More
